Dublin, Jan. 07, 2025 (GLOBE NEWSWIRE) — The “Hyperuricemia Drugs Market Report 2024” report has been added to ResearchAndMarkets.com’s offering.
The hyperuricemia drugs market is experiencing significant growth, projected to rise from $4.39 billion in 2023 to $4.75 billion in 2024, with a further anticipated increase to $6.54 billion by 2028. This growth, exhibiting a CAGR of around 8.2% to 8.3%, is attributed to the growing elderly population, sedentary lifestyles, and increased awareness surrounding the condition.
Advances in treatment options and healthcare spending, coupled with a rising incidence of associated chronic conditions such as kidney disease, hypertension, and diabetes, are propelling this market forward. The global market is responding with a surge in precision medicine, combination therapies, non-invasive treatments, and pharmacogenomic developments, all contributing to heightened drug safety and efficacy.
Regional Insights and Major Players
North America currently leads the hyperuricemia drugs market, followed closely by other key regions around the world. Companies like Pfizer Inc., Merck & Co., Bayer AG, and Teva Pharmaceuticals are focusing on developing innovative treatment options to meet the increasing demand.
Recent market dynamics include significant acquisitions, such as Amgen Inc.’s takeover of Horizon Therapeutics plc, which is anticipated to bolster the development and distribution of new hyperuricemia therapies. Additionally, the rise of generic medication offerings is aimed at enhancing treatment affordability and accessibility.
Market Segmentation and Usage
Hyperuricemia medications are crucial across various market segments, including asymptomatic and symptomatic cases. They are typically administered orally, with dosing tailored to the severity of the condition and the patient’s unique health profile. Medications range from nonsteroidal anti-inflammatory drugs to uricosuric agents, serving both to manage symptoms and prevent the progression of hyperuricemia and associated conditions.
This market spans diverse healthcare settings, from hospitals to specialty clinics, ensuring comprehensive coverage and care is available for those affected. The commitment to innovation and patient care within the hyperuricemia drugs market signifies a pivotal period of growth and development, poised to continue for years to come.
Understanding Market Value
The hyperuricemia drugs market values reflect the revenue generated by companies in the provision of effective treatment options. Revenues within this market are accounted for at the manufacturing level, considering the sale of goods to entities across the distribution chain or direct to end-consumers.
This analytical report underscores the market’s expansion and the increasing need for advanced treatments. The public and healthcare professionals can anticipate a continuing evolution in the hyperuricemia drug landscape in line with patient needs and medical advancements.
For more information about the hyperuricemia drugs market developments and expectations, please contact your local industry specialist.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 175 |
| Forecast Period | 2024 – 2028 |
| Estimated Market Value (USD) in 2024 | $4.75 Billion |
| Forecasted Market Value (USD) by 2028 | $6.54 Billion |
| Compound Annual Growth Rate | 8.3% |
| Regions Covered | Global |
The major companies profiled in this Hyperuricemia Drugs market report include:
- Pfizer Inc.
- Merck & Co.
- Bayer AG
- Sanofi SA
- Myers Squibb Bristol Company
- AstraZeneca plc
- Novartis AG
- GlaxoSmithKline PLC
- Roche Holdings Inc.
- Amgen Inc.
- Boehringer Ingelheim International GmbH
- Teva Pharmaceuticals
- Regeneron Pharmaceuticals Inc.
- Teijin Pharma Limited
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Hikma Pharmaceuticals PLC
- Amneal Pharmaceuticals Inc.
- Glenmark Pharmaceuticals Ltd.
- Kissei Pharmaceutical Co. Ltd.
- Himalaya Wellness Company
- Fuji Yakuhin Co. Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/z0pkv6
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Hyperuricemia Drugs Market
